News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
AustCancer Commences Phase II Clinical Study Of RP101 For Metastatic Pancreatic Cancer
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SYDNEY, Australia--(BUSINESS WIRE)--Dec. 14, 2004--Australian Cancer Technology ("AustCancer") (ASX:ACU) today said it has initiated a Phase II clinical study of RP101 for the treatment of metastatic pancreatic cancer.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
Weight loss
Roche, Zealand’s Amylin Weight Loss Drug Fails To Clear Lilly’s Bar
March 6, 2026
·
3 min read
·
Tristan Manalac
Insights
From Grants to Family Offices: Building a Unified Financing Strategy in Biotech
March 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
March 4, 2026
·
1 min read
·
Heather McKenzie
Insights
Rethinking Biotech’s Valley of Death as Federal Grants and Family Offices Step In
March 4, 2026
·
3 min read
·
Jennifer Smith-Parker
